Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $1.48B
• Dividend Yield: N/A
• Average Volume (3M): 1.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: -100.08%
• EPS Growth: -2.45%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.46
• Shares Outstanding: 106,667,435
• 10 Day Avg. Volume: 1,928,653
• 30 Day Avg. Volume: 1,768,943
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: -1.59K
• Enterprise Value/Gross Profit: -291.77
• Enterprise Value/Ebitda: -2.03
• 1Y Price Target: $15.57
• Price Target Upside: 12.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 57 Neutral
• Price Target: $9.50 ▼(-31.26% Downside)

Amylyx Pharmaceuticals' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and operational losses. While technical analysis shows positive momentum, the company's valuation is weak due to a negative P/E ratio and lack of dividends. The recent halt of the ORION program further adds to the uncertainty, despite some positive developments in other clinical trials.

Positive Factors

Pipeline Expansion

The Fast Track designation for AMX0114 indicates regulatory support and could expedite the development process, enhancing long-term growth prospects.

Strong Financial Position

A robust cash position ensures operational stability and supports ongoing R&D efforts, crucial for future product development and market expansion.

Clinical Trial Progress

Advancement in clinical trials like LUCIDITY for Avexitide demonstrates progress in expanding the product pipeline, essential for long-term revenue growth.

Negative Factors

Revenue Decline

A sharp decline in revenue suggests challenges in product sales and market penetration, impacting the company's ability to sustain operations long-term.

Discontinuation of ORION Program

Halting the ORION program reduces the company's potential product offerings and revenue streams, affecting future growth and market competitiveness.

Cash Flow Challenges

Persistent cash flow issues indicate operational inefficiencies and may limit the company's ability to invest in R&D and other growth initiatives.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with a primary emphasis on conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The company is committed to advancing its lead product, AMX0035, which aims to slow the progression of neurodegenerative disorders by targeting multiple pathways involved in cellular stress and neuroinflammation. Through its scientific expertise and dedication to addressing unmet medical needs, Amylyx is positioned at the forefront of neurotherapeutics.

How the Company Makes Money

Amylyx Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, particularly AMX0035, which has received regulatory approval for use in ALS patients. The company may also explore partnerships with larger pharmaceutical firms for co-development or licensing agreements to expand its product offerings and market reach. Additionally, revenue can be supplemented through grants and funding from governmental and non-governmental organizations aimed at fostering innovation in the biotech sector. As Amylyx progresses through clinical trials and achieves regulatory milestones, it may also benefit from milestone payments from partners, further contributing to its earnings.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Amylyx Pharmaceuticals faces significant financial challenges, with declining revenues and substantial operational losses reflected in negative profit margins. The balance sheet shows a relatively low level of debt and strong equity ratio, although historical negative equity points to potential financial instability. Cash flow analysis reveals persistent cash generation issues, which could impact future operational sustainability.

Income Statement

The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.

Balance Sheet

Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.

Cash Flow

The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-249.00K	87.37M	380.79M	22.23M	285.00K	650.00K
Gross Profit	-1.36M	-37.26M	355.35M	19.24M	233.00K	-23.94M
EBITDA	-194.88M	-290.98M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-187.60M	-301.74M	49.27M	-198.38M	-87.88M	-44.84M
Balance Sheet
Total Assets	194.60M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	180.83M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	5.96M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	26.72M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	167.88M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-165.68M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-165.65M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	83.13M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	65.82M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 13.82 is above the 20-day moving average (MA) of 11.63, above the 50-day MA of 9.58, and above the 200-day MA of 5.73, indicating a bullish trend. The MACD of 1.30 indicates Negative momentum. The RSI at 84.99 is Negative, neither overbought nor oversold. The STOCH value of 90.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	67 Neutral	534.47M	-130.86	-15.65%	―	85.40%	40.95%
ZBIO	58 Neutral	854.00M	-4.40	-50.24%	―	―	―
AMLX	57 Neutral	$1.48B	―	-87.42%	―	-100.08%	-2.45%
BNTC	47 Neutral	369.87M	-10.91	―	―	―	83.28%
ALLO	46 Neutral	272.91M	-1.08	-61.01%	―	-100.00%	30.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Pharmaceuticals Halts ORION Program for AMX0035

On August 27, 2025, Amylyx Pharmaceuticals announced the discontinuation of its ORION program for AMX0035 in adults with progressive supranuclear palsy, as the drug showed no significant differences compared to placebo in primary or secondary outcomes at Week 24. Consequently, the company will halt the Phase 2b trial and open-label extension, and will not proceed with the Phase 3 portion, although safety data remained consistent with previous studies.